Navigation Links
Pharmaxis Announces New Drug Application Submission for Aridol(TM)
Date:3/1/2009

SYDNEY, March 1 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced it had submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Aridol, a bronchial challenge test. Bronchial challenge tests are designed to help in the correct diagnosis and assessment of asthma. The structure and content of the NDA was based on a pre-NDA meeting with the FDA and follows the completion of two international randomized pivotal Phase 3 trials with Aridol involving over 1,000 subjects.

The NDA application is the vehicle through which Pharmaxis formally proposes that the FDA approve a new pharmaceutical for sale and marketing in the U.S. There is currently no FDA approved dry powder bronchial challenge test available in the U.S. and Aridol is the first test of this kind that comes complete and ready to use.

Alan Robertson, Pharmaxis Chief Executive Officer said: "We are delighted to announce this major milestone for Pharmaxis especially in light of the fact that this is believed to be the first such NDA submitted by an Australian company for a drug designed and developed in Australia. Pharmaxis is committed to the development of safe and effective products to help people living with lung diseases, and we look forward to working closely with the FDA over the coming months."

Asthma affects more than 34 million people in the U.S.(1) with an annual economic cost in the U.S. of $19.7 billion(1) and has a substantial impact on the health of a nation. Aridol was developed to assist with improving existing management strategies that help to control asthma and prevent worsening of its symptoms.

Aridol is approved for sale in most major European countries, Australia and Korea. Aridol has been included in the Global Initiative for Asthma
'/>"/>

SOURCE Pharmaxis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... 22, 2011     ... catch up   with   their urban counterparts in adopting technology ...   data spill shows risk of online health records . ... IT and its current challenges? Ambitious national healthcare IT programmes and ...
... Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... leading China-based biotechnology company focused on researching, developing, ... the annual general meeting of shareholders of 3SBio ... at 10:00 a.m., Shenyang time, at our executive ...
Cached Medicine Technology:Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 23SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011 2
(Date:8/23/2014)... The report “Polycarbonate Resin Market by ... 2018” defines and segments the global polycarbonate resin ... revenue and consumption. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ... revenues are forecasted on the basis of major ...
(Date:8/23/2014)... 2014 Having been in the dental field ... Arlington, Texas, saw a need for an effective way to ... I came up with the idea for my design," she ... way for a user to clean the mouth without a ... items. It also helps avoid plaque buildup and maintains proper ...
(Date:8/23/2014)... CA (PRWEB) August 23, 2014 ... trading system created by Greg Marks has been generating ... earlier this month. The commotion surrounding the new product ... an investigative review. , “In recent years ... trading software systems, commonly referred to as robots or ...
(Date:8/23/2014)... Boston, MA (PRWEB) August 23, 2014 ... now have a study aid in preparing for Food ... safety practice test by Dynamic Path. , Dynamic ... study module, which includes more than 200 review questions ... study materials are designed to cover requirements of the ...
(Date:8/23/2014)... August 23, 2014 Youth substance abuse ... It’s no different in Houston, TX. Substance abuse can ... victim to drug and alcohol dependency in higher numbers ... to beat substance abuse, but don’t know where to ... facility can be a challenge because most treatment options ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay News) ... the risk of getting breast cancer, but women who take ... risk of dying from the disease, a new study suggests. ... particular type of cancer that is easier to treat," explained ...
... Ariz., Dec. 12 Roberta Kalafut, D.O., just announced her ... to a close the worst abuses of power by the ... unjust disciplinary actions, particularly against her competitors, and stonewalling by ... , "We applaud Kalafut,s resignation," said AAPS Executive ...
... Fair Offers New Chemists and Chemical Engineers an Opportunity to ... , PRINCETON, N.J., Dec. 12 Informex ... the upcoming InformexUSA exhibition in San Francisco free of charge. ... 25 and under to learn more about the chemical technologies ...
... saw disease stabilize or improve, study shows , , ... combination of medicines designed to boost immune function ... interim results from an ongoing Mayo Clinic study. ... immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved ...
... At its 12th annual holiday gala The,Teddy Bear ... Award to Steve,Mosko, President of Sony Pictures Television ... to children with special needs. Grammy(R),winning singer-songwriter Kenny ... of the Heart. Long standing friend and colleague ...
... YORK, Dec. 12 In his last public remarks as,the ... Lilly and Company (NYSE: LLY ), today said ... markets and regulatory environments,encourage and reward companies for the long-term, ... bench to the bedside. , ...
Cached Medicine News:Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Informex Invites Young Chemists to Attend InformexUSA 2Health News:Informex Invites Young Chemists to Attend InformexUSA 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 3
Right angled 5 mm blunt hook. Overall length: 9.9 inches....
Fine short working end. Overall length: 4.9 inches. Most popular size or model....
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches....
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall ...
Medicine Products: